Cancer Center Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden.
Mol Oncol. 2019 Mar;13(3):517-520. doi: 10.1002/1878-0261.12450. Epub 2019 Feb 1.
The main components of the cancer research continuum are basic/preclinical research, early and late clinical research and, after the adoption of an innovation by the healthcare or health organisations, outcomes research. Translational cancer research, defined as a coherent cancer research continuum, is mandatory to address the increasing burden of cancer effectively. The growing cancer problem can only be significantly modified by concerted action involving prevention to decrease incidence, early detection and treatment to increase the cure rate, and personalised/precision cancer medicine to adapt early detection and treatment to the biology of a tumour with the aim of increasing the cure rate, prolonging survival and improving health-related quality of life. By definition, translational cancer research for therapeutics has a focus on patients' needs and for prevention for individuals at-risk. Consequently, to increase the effectiveness of translational research, the different components of the cancer research continuum need to be better connected to the fundamental aim of a mission-oriented approach to cancer (Celis and Pavalkis, ).
癌症研究连续体的主要组成部分包括基础/临床前研究、早期和晚期临床研究，以及医疗保健或卫生组织采用创新后进行的结果研究。转化癌症研究被定义为一个连贯的癌症研究连续体，对于有效应对癌症负担的增加是强制性的。只有通过涉及预防以降低发病率、早期发现和治疗以提高治愈率，以及个性化/精准癌症医学以适应肿瘤生物学，从而提高治愈率、延长生存时间和改善与健康相关的生活质量的协同行动，才能显著改变日益严重的癌症问题。根据定义，治疗性转化癌症研究侧重于患者的需求，而预防则侧重于有风险的个人。因此，为了提高转化研究的效果，需要更好地将癌症研究连续体的不同组成部分与以任务为导向的癌症方法的基本目标（Celis 和 Pavalkis，）联系起来。
